Login to Your Account



Other News To Note


Wednesday, March 28, 2012
• Kancera AB, of Stockholm, Sweden, said its ROR inhibitors showed an effect in a model of human pancreatic cancer. The compounds were superior in efficacy to gemcitabine. The study was done in collaboration with Matthias Lohr, a professor at the Karolinska Institutet in Stockholm.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription